CONTROLLED SUB-TESTOSTERONE

104th Regular Session Introduced by Mary Edly-Allen and 4 co-sponsors

Illinois SB 3323 would establish state regulation and licensing for handling sub-testosterone to ensure safety, oversight, and enforcement.

Rule 3-9(a) / Re-referred to Assignments

Illinois SB 3323 (104th Session) – CONTROLLED SUB-TESTOSTERONE

Purpose and intent

The bill is titled "CONTROLLED SUB-TESTOSTERONE." Based on the title and typical legislative framing, it aims to regulate a specific hormone or hormone-related substance referred to as “sub-testosterone” within Illinois. The exact statutory language is not provided, but the bill’s intent is to establish rules, oversight, and controls around this substance to address safety, health, or public policy concerns.

Key provisions and changes (as implied by typical structuring of such bills)

Regulatory framework: Establishes or modifies legal controls over the production, distribution, possession, or use of sub-testosterone.

Licensing and oversight: May require licenses or registrations for entities handling the substance (manufacturers, distributors, retailers, or clinics).

Safety and quality standards: Could set purity, labeling, storage, testing, and reporting requirements to ensure safe handling.

Restrictions and prohibitions: Likely enumerates prohibited activities (e.g., unauthorized sale to certain groups, distribution without a license, or use in prohibited contexts).

Penalties and enforcement: Specifies penalties for violations and designates enforcement mechanisms (state agencies, inspections, compliance actions).

Consumer protections: Possible provisions to protect patients or consumers, including informed consent, warnings, or restriction of access to minors.

Data and reporting: May require periodic reporting to a state agency, including adverse events or inventory tracking.

Effective dates and transition: Provides date of enactment and any phase-in periods for compliance.

Who and what is affected

Entities involved with sub-testosterone: Manufacturers, distributors, retailers, clinics, and healthcare providers handling the substance.

Consumers/patients: Individuals who would be affected by access, prescription, or use restrictions.

State agencies: Likely to involve health, public safety, or narcotics/controlled substances agencies responsible for enforcement, licensing, and compliance.

Procedural/timeline aspects

Introduction and sponsorship: Filed February 3, 2026 by Sen. Adriane Johnson, with multiple co-sponsors (Sens. Mary Edly-Allen, Emil Jones III, Graciela Guzmán, Rachel Ventura).

Committee considerations: Referred to Assignments on Feb 3, 2026; subsequently assigned to Executive (Feb 17, 2026). Rules and deadlines indicate ongoing committee action.

Schedule milestones:

Rule 2-10 Committee Deadline established for March 27, 2026.
Rule 2-10 deadline extended or adjusted; additional actions on April 14 and April 24, 2026 show continued movement through committees.
As of the latest action (April 24, 2026), the bill was re-referred to Assignments.

Potential impact

Public health and safety: Aims to improve safety around a regulated substance, potentially reducing misuse and ensuring quality standards.

Market/compliance burden: May impose licensing, record-keeping, and reporting requirements on entities handling sub-testosterone, impacting operations and compliance costs.

Accessibility and control: Could tighten or shape access, particularly if the substance has therapeutic uses or potential for abuse.

Enforcement: Establishes state-level oversight with penalties for non-compliance, influencing enforcement priorities.

Notes

The exact statutory text, definitions (e.g., what qualifies as “sub-testosterone”), and specific regulatory mechanisms are not provided here. For precise requirements, penalties, and timelines, reviewing the bill’s full wording and fiscal impact notes once available would be essential.